Macomics to receive an up front & R&D funding, and is also eligible to receive success-based milestones along with royalties based on global net sales. Ono gets an exclusive option to license rights globally to the candidates for further development and commercialization
Macomics will use its ENIGMACT macrophage drug discovery platform for the identification and characterization of new immuno-oncology antibody drugs against the novel target of interest
To find new targets and reveal disease-specific target biology, Macomics’ ENIGMAC macrophage drug discovery platform combines high-volume human data sets, personalized cell models, and human macrophage genome editing technology
Ref: Ono Pharmaceutical | Image: Ono Pharmaceutical
Related News:- Ono Pharmaceutical’s Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the MFDS Approval as 1L Treatment of Esophageal Squamous Cell Carcinoma in South Korea
